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ABSTRACT
The optimal management of patients with initially refractory acute myeloid leukemia is unknown. We analyzed
the outcomes of 68 adult patients (median age, 37 years) with acute myeloid leukemia in first complete
remission with initially refractory disease who were treated with matched sibling (n  44) or unrelated donor
(n  22) stem cell transplantation or who received transplants from other donors (n  2). Thirty-one patients
took 2 courses of chemotherapy to achieve first complete remission, a further 31 took 3 courses, and 6 patients
took 4 or 5 courses. Ten patients (15%) had adverse cytogenetics. Patients were mainly conditioned with
cyclophosphamide and total body irradiation (87%). Four patients (6%) did not engraft by day 28; 2 of these
engrafted at 47 and 60 days. Grades II to IV and III/IV acute graft-versus-host disease (GVHD) were seen in
34% and 14% of patients, respectively. Chronic GVHD was seen in 50% of patients. The estimated actuarial
disease-free and overall survivals were 34% and 37%, respectively, at 4 years. The performance status of
survivors is good; 82% of patients have Karnofsky scores of 90 to 100. On multivariate analysis, overall and
disease-free survival were associated with adverse cytogenetics (P  .055 and .023). Approximately one third of
patients survived 4 years after allogeneic stem cell transplantation for initially refractory acute myeloid leukemia in
first complete remission: relapse and treatment-related mortality were the major causes of treatment failure.
Further studies are needed to determine the optimal conditioning regimens and GVHD prophylaxis.
© 2006 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
The role of allogeneic stem cell transplantation
SCT) in the management of adults with acute my-
loid leukemia (AML) in ﬁrst complete remission
CR1) is uncertain. Prospective trials using biological
andomization show statistically signiﬁcantly superior s
B&MTisease-free survival in allografted patients compared
ith those receiving best alternative therapy, but they
o not show signiﬁcantly improved overall survival
1,2]. However, patients with poor-risk cytogenetics
o seem to have a superior outcome with a matched
ibling allograft [3].
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2The Medical Research Council trials performed
ver the last 10 years have done much to help us
tratify risk in adults with AML. Although there are
ome disagreements about which cytogenetic abnor-
alities confer an adverse prognosis, there is wide-
pread agreement that the response to ﬁrst-line che-
otherapy is of immense prognostic signiﬁcance [4].
he AML 10 and AML 12 studies found that patients
ith 15% blasts after the ﬁrst course of chemother-
py have a low chance of prolonged disease-free sur-
ival with further chemotherapy alone and have sug-
ested that these patients be regarded as high risk and
andidates for sibling allografts or unrelated donor
llografts if they lack a matched sibling donor [4-6].
he outcome of this therapeutic strategy is, however,
nclear, and it seems likely that patients refractory to
hemotherapy will also have a relatively poor outcome
fter high-dose chemoradiotherapy and a possible im-
unologic graft-versus-leukemia effect, although this
s uncertain.
By using data retrospectively collected by the Brit-
sh Society of Blood and Marrow Transplantation
egistry and additional data obtained by reference to
atient records from the submitting transplant cen-
ers, we performed a national study of patients who
ad more than 15% blasts after the ﬁrst course of
hemotherapy but then subsequently achieved a CR
nd patients who took more than 2 courses of chemo-
herapy to achieve a CR. We described the toxicities
f these allogeneic transplantations and analyzed the
actors associated with a successful outcome.
ATIENTS AND METHODS
atient Identification and Definition
To be eligible for inclusion in the study, the pa-
ient had to have had an allograft for AML in CR1 and
o have satisﬁed 1 of the following criteria: (1) 15%
lasts present after the ﬁrst course of chemotherapy
nd (2) 3 courses of chemotherapy to achieve CR1.
he British Society of Blood and Marrow Transplan-
ation database records the number of courses of che-
otherapy required to achieve CR. All patients with
3 courses were included on the study. All patients
ho required 2 courses of chemotherapy to achieve a
R were analyzed further, and centers were asked to
ist the patients who had15% blasts present after the
rst course of chemotherapy. Initially 103 patients
ere identiﬁed in 18 centers before the blast count
fter course 1 was ascertained. One center had 3 pa-
ients in this group, but none had 15% blasts after
ourse 1. Two centers (n  7) declined participation;
5 centers contributed patients to the study. The
tandard deﬁnition of CR was used: 5% blasts with
vidence of count recovery and resolution of organo-
egaly, but no duration was speciﬁed because these
atients proceeded to transplantation rapidly. i
94The following hospitals contributed patients: Uni-
ersity College (n  14), Royal Free Hospital (n 
3), Nottingham City Hospital (n  12), Royal Liv-
rpool Hospital (n  7), Bristol Children’s Hospital
n  5), Addenbrooke’s Hospital (n  4), John Rad-
liffe Hospital (n  3), Royal Marsden Hospital (n 
), St. James’ Leeds (n 2), St. James’ Dublin, Belfast
ity Hospital, St. George’s Hospital, Leicester Royal
nﬁrmary, King’s College Hospital, and the Christie
anchester (n  1 patient each).
emographic Data
The following demographic and transplantation
ata were collected: age, sex, age of donor, cytomeg-
lovirus status of donor and recipient, conditioning
egimen, use of in vivo or ex vivo T-cell depletion,
alvage therapy, cytogenetic abnormalities, dose of total
ody irradiation (TBI), and number of fractions. Post-
ransplantation data were collected with regard to
xtramedullary toxicity, use of high-dose antifungal
herapy, acute and chronic graft-versus-host disease
GVHD), time to relapse, patient remission status at
ast follow-up, and patient Karnofsky score at last
ollow-up. The time to engraftment was the ﬁrst of 3
ays in which the neutrophil count was0.5 109/L.
tatistical Analysis
The study aimed to examine the following major
nd points: survival, disease-free survival, transplant-
elated mortality, incidence of grade II to IV acute and
hronic GVHD, and cause of death. Survival, disease-
ree survival, relapse rate, transplant-related mortality,
nd chronic GVHD were assessed by Kaplan-Meier
urvival analysis. Factors that inﬂuenced overall and
isease-free survival, transplant-related mortality,
nd relapse rate were assessed. All relevant clinical
actors were put into the models to determine
hether they affected the chance of survival. Cox
roportional hazard regression models were used
or overall and disease-free survival, whereas cumu-
ative incidence analysis was used for competing risk
odels of transplant-related mortality and relapse
ate. The factors assessed for effect included patient
ex and age, donor age, female donor to male recipi-
nt, French-American-British (FAB) type, adverse
ytogenetics, type of donor (related or unrelated;
atched or mismatched), time from diagnosis to
ransplantation, number of courses of chemotherapy
o achieve CR, source of stem cells (bone marrow or
eripheral blood), fractions of TBI conditioning, dose
f TBI, acute or chronic GVHD prophylaxis, and
-cell depletion. The R software package was used for
ll statistical analyses described [7].
Factors that were signiﬁcant (P  .05) in univar-
ate models of overall or disease-free survival were
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BB&MTncluded in a multivariate Cox model. The median fol-
ow-up of survivors was 4.1 years (range, 1-14.4 years).
ESULTS
atient and Transplant Characteristics
Sixty-eight patients underwent transplantation in
5 centers from 1989 to 2003. Their pretransplanta-
ion clinical characteristics are shown in Table 1. Two
atients had secondary AML. Intermediate- to high-
ose cytosine arabinoside–containing regimens were
ost frequently used to obtain remissions. Twenty-
wo patients had unrelated donors (32%), 44 received
tem cells from matched sibling donors (65%), and 2
eceived syngeneic and mismatched related trans-
lants. Because of the prolonged time period during
hich patients underwent transplantation and differing
nstitutional policies regarding acceptable matches, the
egree of matching of the unrelated donors varied. All
atients had serologic class I typing and molecular
lass II typing, and 8 (36%) of 22 were mismatched.
he median time from diagnosis to transplantation
as 188 days (range, 70-471 days). Fifty-seven pa-
ients (84%) had TBI-containing conditioning; 32 had
4.4 Gy (24 in 8 fractions in 4 days and 8 in 6 fractions
n 3 days), and 16 had single-fraction TBI with a
edian dose of 7.5 Gy (range, 6.84-10.0 Gy). The
emaining 9 patients received 11 to 13 Gy of TBI.
ngraftment
Engraftment data were available in 64 evaluable
atients. Two patients (3%) did not engraft; 1 had an
nrelated donor, and the other had a sibling donor.
wo additional patients (sibling donors) engrafted at
ays 47 and 60; we have classiﬁed these patients as
aving primary graft failure, and, therefore, 6% of
atients did not engraft. The median time to engraft-
ent was 15 days (range, 10-29 days). The time to
able 1. (Continued)
Variable Data
n vivo or ex vivo T-cell depletion 29
ntravenous monoclonal antibodies 22
lemtuzumab “in the bag” 7
D34 selection 5
ra-C indicates cytosine arabinoside; G-CSF, granulocyte colony-
stimulating factor.
Of the 32 patients who received 14.4 Gy, 8 received this in 6
fractions and 24 in 8 fractions.
Of the 57 patients received additional agents: melphalan 1, thio-
tepa 5, ﬂudarabine 2, busulphan 3, and other/unknown 3.
Eight patients received additional steroids as GVHD prophylaxis:
cyclosporin A (CsA) alone 3, methotrexate (MTX) alone 2, and
CsA  MTX 3.able 1. Clinical Characteristics of Patients and Details of
ransplantation
Variable Data
ale 38
emale 30
ge at transplantation (y) 36 (17.8-59.8)
AB classification
M0 7
M1 10
M2 21
M3 5
M4 9
M5 6
M6 4
M7 2
Unknown 2
ytogenetics
Normal 27
Abnormal 28
Failed 4
Unknown/not done 9
hromosome 5 abnormality 1
hromosome 7 abnormalities 4
hromosome 5 and 7 abnormalities 1
omplex abnormalities 3
omplex abnormalities  chromosome 5
abnormal 1
ast chemotherapy before transplantation
Fludarabine, Ara-C, G-CSF 11
Fludarabine, Ara-C 4
Fludarabine, Ara-C, G-CSF, idarubicin 13
Mitoxantrone, Ara-C 9
Ara-C, daunorubicin, etoposide 6
Amsacrine, Ara-C, etoposide 5
Daunorubicin, Ara-C, thioguanine 8
Other 4
None 1
Unknown 7
umber of courses of chemotherapy to CR
2 31
3 31
4 3
5 3
edian diagnosis to transplantation
interval (d) 188 (70-471)
emale donor/male recipient 11
tem cell source
Marrow 48
Peripheral blood 20
onor type
Matched sibling 44
Unrelated donor 22
Mismatched sibling 1
Syngeneic 1
BI
None 11
Single fraction 16
12-13 Gy 4
13-14 Gy 5
14.4 Gy* 32
yclophosphamide/TBI† 57
usulphan/cyclophosphamide 4
usulphan/melphalan 1
ludarabine/melphalan 5
ludarabine/busulphan 1
dditional GVHD prophylaxis‡
Cyclosporine, no methotrexate 15
Cyclosporine/methotrexate 32ngraftment is unknown in 15 patients. The median
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2imes to unsustained platelet counts of 20 and 50 
09/L were 21 and 24 days, respectively (Table 2).
raft-versus-Host Disease
Sixty-six patients were evaluable for acute GVHD.
wenty-two patients (34%) experienced grade II to
V GVHD, and 9 (14%) experienced grade III or IV.
t is interesting to note that 8 of the 9 patients with
evere acute GVHD received stem cells from matched
ibling donors. Of these 9 patients, 3 survived, and all
ad grade III acute GVHD. However, 23 patients
35%) had grade I GVHD, and this means that 45
atients had some acute GVHD.
Fifty-four patients survived to day 100 and were
ssessable for chronic GVHD. Twenty-ﬁve patients
50% at 2 years; 95% conﬁdence interval [CI], 33%-
2%; 13 matched siblings, 11 unrelated, and 1 mis-
atched sibling) had chronic GVHD. The median
ime to development of chronic GVHD was 121 days
range, 100-410 days), and in 14 patients it was from
ontinuing acute GVHD.
oxicity/Death
In total, 43 patients have died: 26 (38%) of trans-
lant-related causes. Two patients died of secondary
alignancy, 1 of metastatic rectal cancer, and the other
f pulmonary adenocarcinoma. One patient died of
uillain-Barré syndrome. This patient’s death was
lassiﬁed as transplant related. Four patients (6%) had
ocumented veno-occlusive disease. Seventeen pa-
ients received high-dose systemic antifungal therapy,
ut information is not available concerning how many
atients had deﬁnite or probable invasive fungal in-
ection, and data are not available concerning a third
f the patients. The causes of death are shown in
able 3. GVHD, infection, and pulmonary deaths
ere the most common causes of transplant-related
able 2. Major Transplantation Outcomes
Variable Data
cute GVHD (66 evaluable)
No GVHD 21 (32%)
Grade I 23 (35%)
Grade II-IV 22 (33%)
Grade III-IV 9 (14%)
hronic GVHD (54 evaluable) 25 (50%)
elapse 20
elapse rate at 5 y 31% (95% CI, 19%-42%)
edian time to relapse (d) 172 (94-540)
live 25 (37%; 95% CI, 26%-51%)
arnofsky score at last follow-up
(2 patients not evaluated)
13
90 5
80 3
70 1eath. d
96elapse
Twenty patients have relapsed, and the cumulative
ncidence of relapse (treating transplant-related mor-
ality as a competing risk) at 4 years was 31% (95% CI,
9%-42%). Two patients are alive in a subsequent
emission lasting 8 months and 7.5 years. The median
ime to relapse was 172 days (range, 94-540 days). Of
he 20 patients who relapsed, 7 received palliative
reatment only, and the therapy of 4 patients is un-
nown. Five patients had chemotherapy only, 1 had
emtuzamab, and 3 had donor lymphocyte infusion.
he patient who received gemtuzamab and 1 of the
atients who received donor lymphocyte infusion sur-
ive in CR2.
urvival and Current Status
Twenty-ﬁve patients (37%) survive, and all but 1
re in CR, although 2 patients are in CR2. The per-
ormance status of survivors is good: 18 patients have
Karnofsky score of 90 or 100. Estimated actuarial
robabilities of overall and disease-free survival are
hown in Figures 1 and 2. The median overall and
igure 1. Probability (%) of overall survival (OS) in years. Tick
arks indicate surviving patients. Dotted lines indicate 95% conﬁ-
able 3. Causes of Death
Variable Data
cute myeloid leukemia 17
raft-versus-host disease 5
neumonitis/diffuse alveolar damage 7
nfection* 10
econdary malignancy 2
ther† 2
otal 43
Infections: viral 3, fungal 1, multiple pathogens 4.
Hemorrhage 1, Guillain-Barré syndrome 1.ence intervals.
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Allografting for First Induction Chemotherapy Refractory AML in CR1
Bisease-free survivals are 12 months (95% CI, 7
onths to 6 years 4 months) and 10.6 months (95%
I, 5 months to 1 year 11 months), respectively. Es-
imated actuarial survival at 4 years is 39%, and dis-
ase-free survival is 34% (Figures 1 and 2). Although
here is no clear plateau to the survival curve, the 3
vents at 5 years or later are transplant-related deaths
1 of them metastatic rectal carcinoma), and there
ere no relapses after 18 months after transplantation.
nivariate and Multivariate Analysis of Factors
redictive of Relapse and Survival
Ten of 22 unrelated donor recipients survive,
ompared with 15 of 44 sibling allograft recipients
not signiﬁcant). Only 1 of 7 patients with mismatched
Figure 2. Probability (%) of disease-free survival (DFS) in years.
igure 3. Probability (%) of overall survival in years according to
pytogenetics.
B&MTnrelated donors survives, but because of small num-
ers and the lack of uniform typing, these data should
e treated with caution. The overall survival at 1 year
s 67% for matched and 29% for mismatched unre-
ated donor recipients (P .15). Of the 6 patients with
ismatched donors, 3 died of relapse, and 3 had trans-
lant-related deaths.
The following factors were examined on univari-
te analysis to see whether they were associated with
urvival or relapse: type of donor, patient and donor
ge, time from diagnosis to transplantation, sex, poor-
rognosis cytogenetics (chromosome 5 and 7 or com-
lex abnormalities) (Figures 3 and 4), acute or chronic
VHD, number of courses of chemotherapy to achieve
R, mismatched unrelated transplant, FAB type, fe-
ale donor to male recipient versus all others, bone
arrow versus peripheral blood, single fractions ver-
us fractionated, 14.4 Gy versus all other fractionated
oses, cyclosporin A plus methotrexate versus all other
rophylaxis, and T-cell depleted versus not (within
nrelated transplant groups). The following factors
ffected overall survival signiﬁcantly. A prolonged
ime from diagnosis to transplantation (180 days) was
ssociated with better median survival (1796 versus 225
ays; P  .034). Associated with this was that patients
ho had 3 courses of treatment to achieve CR had a
uperior relapse-free survival (P  .04). Cytogenetics
id correlate with survival. The median overall sur-
ivals of patients with abnormalities of chromosomes
and 7 or complex cytogenetics were compared with
hose of patients with other cytogenetic abnormalities
r normal cytogenetics, and the differences were sig-
iﬁcant (135 versus 675 versus 698 days; P  .017).
isease-free survival was also signiﬁcantly worse in
igure 4. Probability of disease-free survival (%) in years according
o cytogenetics.atients with poor-risk cytogenetics (P  .004). Sur-
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2ival was not signiﬁcantly associated with age, FAB
lass, donor type, acute or chronic GVHD, donor age
r sex, stem cell source, or the dose or fractionation of
BI. GVHD did not affect the chance of relapse.
ifteen patients had neither acute nor chronic
VHD; the overall survival of these patients at 2 years
as 40%, similar to the outcome of all patients.
A multivariate analysis was then performed of the
actors signiﬁcantly associated with survival and dis-
ase-free survival on univariate analysis (Table 4). Ad-
erse cytogenetics were signiﬁcantly associated with
elapse and disease-free survival, and there was a trend
oward it’s being associated with overall survival. In
he multivariate analysis, time from diagnosis was no
onger associated signiﬁcantly with overall survival.
ISCUSSION
It is well known that high-dose chemoradiother-
py and an immunologic graft-versus-leukemia effect
an cure patients in whom standard-dose chemother-
py for AML has produced inadequate cytoreduction,
ut the outcome of allografting AML patients who are
nitially refractory to chemotherapy and then achieve
R has not been speciﬁcally described in the litera-
ure. In fact, allogeneic SCT can cure a minority of
atients with completely refractory acute leukemia.
homas et al. [8] ﬁrst reported the outcome of 100
uch patients nearly 30 years ago. Patients with ini-
ially refractory AML who subsequently do respond to
hemotherapy potentially have a better prognosis, but
ittle is written about these patients as a separate
roup.
The outcome of patients with AML with resistant
isease after course 1 of chemotherapy is poor, with
2% 5-year survival from the start of course 2 [5]. In
he Medical Research Council studies, patients with
hemoresistant disease are grouped with patients with
dverse cytogenetics into an overall poor-risk group.
hese studies have not shown that allogeneic bone
arrow transplantation was of beneﬁt in this poor-
isk group (on a donor versus no-donor analysis), but
he numbers of patients receiving an allograft were
mall because many relapsed early. It may be difﬁcult
o decide about the value of allograft when such a
able 4. Multivariate Analysis
End Point Covariates P Value
S Time from diagnosis to transplantation .120
Cytogenetics (chromosome 5/7/complex
vs. rest)
.067
FS Time from diagnosis to transplantation .048
Cytogenetics (chromosome 5/7/complex
vs. rest)
.023
S indicates overall survival; DFS, disease-free survival.arge proportion of patients in the donor group did r
98ot receive the assigned therapy [9]. There is clearly
ome overlap between these risk groups, but to aid
linical decision making, we thought that it would be
elpful to examine the outcome of patients with che-
orefractory AML separately.
The overall outcome of patients who have allo-
rafts for AML in CR1 is good, with 70% prolonged
urvival in patients with matched siblings [9] and ap-
roximately 50% in those who have unrelated donor
llografts for high-risk AML in CR1 [10,11,12]. This
tudy shows that, on a national multicenter basis,
pproximately one third of patients with poorly re-
ponsive AML who do subsequently achieve CR can
urvive 4 years after sibling or unrelated donor trans-
lantation. We were unable to collect detailed quality-
f-life data, but Karnofsky scores at last follow-up
uggest that the performance status of survivors is
ood. The median follow-up of the patients in this
eries is 4 years, but 7 patients have not reached 2
ears after transplantation and are still at high risk of
elapse.
The patients with poor-risk cytogenetics had a
igniﬁcantly poorer survival on multivariate analy-
is. It is of interest that acute and chronic GVHD
id not affect survival in this series and did not
nﬂuence the risk of relapse. This is in marked
ontrast with some recent series [13]. The encour-
ging survival in patients without acute or chronic
VHD suggests that it may be reasonable to use
ransplantation protocols that avoid GVHD in
icker patients, who would not tolerate this compli-
ation well. The outcome of sibling and unrelated
onor transplantations was not signiﬁcantly differ-
nt, and this study shows that unrelated donor SCT,
f a donor can be identiﬁed in time (Marks et al.,
npublished data), can result in a signiﬁcant pro-
ortion of survivors. The outcome of patients with
ismatched unrelated donors may be less good, but
ecause the typing was not uniform in this multi-
enter retrospective study and because numbers
ere small, this should be interpreted with caution.
More than 50% of patients with primary resis-
ant AML may achieve a CR with salvage chemo-
herapy [14]. However, after the ﬁrst course of che-
otherapy, many do not completely recover their
lood counts, and the persistent severe neutropenia
ay be associated with considerable morbidity, thus
aking some of these patients worse candidates for
subsequent allograft. The major single reason for
reatment failure in this series was relapse, but
ransplant-related mortality was also signiﬁcant.
nly 5 patients in our series had reduced-intensity
onditioning transplantations, and 2 survive. These
umbers are insufﬁcient to determine whether this
pproach warrants further investigation, but given
he poor condition of many patients with initially
efractory AML, it is likely that less toxic regimens
w
r
d
C
p
d
s
b
o
c
p
t
d
A
o
m
t
m
d
b
t
F
c
d
r
c
s
h
t
t
p
M
d
u
c
w
w
m
f
U
t
p
r
t
A
f
l
p
d
q
C
B
R
1
1
1
1
Allografting for First Induction Chemotherapy Refractory AML in CR1
Bill be explored further in the future. There are no
educed-intensity conditioning studies speciﬁcally
evoted to patients with initially refractory AML in
R, but it may be possible to extrapolate from other
atients with high-risk AML. More intense re-
uced-intensity conditioning regimens may be as-
ociated with better progression-free survival [15]
ut have more toxicity. The approach is feasible in
lder, inﬁrm patients, and medium-term survival
an be achieved [16]. This study [16] found that
atients with GVHD had less disease progression;
his differs from our study. There are few published
ata with alemtuzumab-containing regimens for
ML.
Clearly this study has signiﬁcant limitations if
ne is using these data to decide whether to recom-
end allogeneic SCT to these patients. However,
he practicalities of performing a randomized study
ake it unlikely that one will be performed. A
egree of selection bias will be present in this series
ecause ﬁtter patients are more likely to undergo
ransplantation. In addition, we lack data about
LT3 mutations and whether they affected out-
ome [6]. Furthermore, we are unable to comment
eﬁnitively as to whether mismatching between un-
elated donors and recipients affects outcome, be-
ause the technology of typing has evolved over the
tudy time period.
In summary, although there are no randomized
ead-to-head comparisons of allografting versus con-
inued chemotherapy in patients with initially refrac-
ory AML in CR, it seems reasonable to continue a
olicy of offering an allograft in ﬁrst remission.
atched unrelated donors are acceptable if no sibling
onor is available. The results seem less good if the
nrelated donor is mismatched or if there are adverse
ytogenetics. Further investigations should explore
hether we can harness a graft-versus-leukemia effect
ith less transplant-related toxicity. This approach
ay increase the number of patients who are eligible
or a potentially curative procedure.
NCITED REFERENCES
This section comprises references that occur in
he reference list but not in the body of the text. Please
osition each reference in the text or delete it. Any
eferences not dealt with will be retained in this sec-
ion:[10].
CKNOWLEDGMENTS
The Leukaemia Research Fund provided support
or this work (grant no. 03/100; D.I.M.). We would
ike to thank all the data managers and transplant
hysicians of the participating centers for providing
B&MTata and responding to numerous additional data re-
uests. This work was performed on behalf of the
linical Trials Committee of the British Society of
lood and Marrow Transplantation.
EFERENCES
1. Zittoun RR, Mandelli F, Willemze R, et al. Autologous or
allogeneic bone marrow transplantation compared with inten-
sive chemotherapy in acute myeloid leukemia. N Engl J Med.
1995;332:217-223.
2. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared
with autologous stem cell transplantation in the treatment of
patients younger than 46 years with acute myeloid leukemia
(AML) in ﬁrst complete remission (CR1): an intention-to-treat
analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;
102:1232-1240.
3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic anal-
ysis predicts outcome of preremission and postremission ther-
apy in adult acute myeloid leukemia: a Southwest Oncology
Group/Eastern Cooperative Oncology Group Study. Blood.
2000;96:4075-4083.
4. Burnett AK, Wheatley K, Goldstone AH, et al. The value of
allogeneic bone marrow transplant in patients with acute my-
eloid leukaemia at differing risk of relapse: results of the UK
MRC AML 10 trial. Br J Haematol. 2002;118:385-400.
5. Wheatley K, Burnett AK, Goldstone AH, et al. A simple,
robust, validated and highly predictive index for the determi-
nation of risk-directed therapy in acute myeloid leukaemia
derived from the MRC AML 10 trial. United Kingdom Medical
Research Council’s Adult and Childhood Leukaemia Working
Parties. Br J Haematol. 1999;107:69-79.
6. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a
FLT3 internal tandem duplication in patients with acute my-
eloid leukemia (AML) adds important prognostic information
to cytogenetic risk group and response to the ﬁrst cycle of
chemotherapy: analysis of 854 patients from the United King-
dom Medical Research Council AML 10 and 12 trials. Blood.
2001;98:1752-1759.
7. R Development Core Team. R: A Language and Environment for
Statistical Computing. Vienna, Austria: R Foundation for Statis-
tical Computing; 2005.
8. Thomas ED, Buckner CD, Banaji M, et al. One hundred
patients with acute leukaemia treated by chemotherapy, total
body irradiation, and allogeneic marrow transplantation. Blood.
1977;49:511-533.
9. Frassoni F. Randomised studies in acute myeloid leukaemia: the
double truth. Bone Marrow Transplant. 2000;25:471-473.
0. Papadopoulos E, Carabasi MH, Castro-Malaspina H, et al.
T-cell-depleted allogeneic bone marrow transplantation as pos-
tremission therapy for acute myelogenous leukemia: freedom
from relapse in the absence of graft-versus-host disease. Blood.
1998;91:1083-1090.
1. Marks DI, Bird JM, Hunt L, et al. T-cell depleted unrelated
donor bone marrow transplantation for acute myeloid leuke-
mia. Biol Blood Marrow Transplant. 2000;6:646-653.
2. Sierra J, Bjerke J, Hansen J, et al. Marrow transplants from
unrelated donors as treatment for acute leukemia. Leuk Lym-
phoma. 2000;39:495-507.
3. Neudorf S, Sanders J, Kobrinsky N, et al. Allogeneic bone
marrow transplantation for children with acute myelocytic leu-
299
11
1
G. Cook et al.
3kemia in ﬁrst remission demonstrates a role for graft versus
leukemia in the maintenance of disease-free survival. Blood.
2004;103:3655–3361.
4. Tallman MS, Gilliland DG, Rowe JM. Drug therapy of acute
myeloid leukemia. Blood. 2005.
5. De Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative
versus reduced-intensity conditioning regimens in the treatment
of acute myeloid leukemia and high-risk myelodysplastic syn-
00drome: dose is relevant for long-term disease control after
allogeneic hematopoietic stem cell transplantation. Blood.
2004;104:865-872.
6. Martino R, Caballero MD, Simon JA, et al. Evidence for a
graft-versus-leukemia effect after allogeneic peripheral blood
stem cell transplantation with reduced-intensity conditioning in
acute myelogenous leukemia and myelodysplastic syndromes.
Blood. 2002;100:2243-2245.
